Cognitive Impairment and Fatigue After Mild to Moderate COVID-19

Launched by DANDERYD HOSPITAL · Sep 15, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how some people experience ongoing problems like fatigue and difficulty thinking after having mild to moderate COVID-19. The researchers want to understand how these issues, known as cognitive impairment and fatigue, can affect daily life and whether factors like depression and sleep problems might play a role. They are looking for participants aged 18 and older who have had COVID-19 for more than three months and are still struggling with these symptoms. However, those with certain other health conditions, severe mental illness, or who are not fluent in Swedish cannot participate.

If you decide to join the study, you’ll undergo tests to evaluate your cognitive abilities and fatigue levels. The goal is to gather information that could help improve the understanding and treatment of these long-lasting symptoms. This trial is currently recruiting participants, and your involvement could contribute to important findings that help others facing similar challenges after COVID-19.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Persons 18 years and older with a history of (\> 3 months) verified COVID-19 (PCR / rapid test / antibody) or an infection that is most likely a SARS-CoV-2 infection (e.g., a close relative had a verified infection that coincided in time with the patient's illness) and who have persistent problems with cognitive impairment or fatigue affecting the return to previous activities / employment.
• Exclusion Criteria:
• • Dominant recurrent and / or fluctuating symptoms of infection, circulatory, respiratory or cardiac problems.
• • Co-morbidities that may cause cognitive impairment such as neurodegenerative disease, substance abuse, severe mental illness (eg. schizophrenia, mano depressive disorder) or severe depression.
• • Not fluent in Swedish, as test and self-reports rely on good mastering of the Swedish language.
• • Severe premorbid visual impairment.
• Additionally for the fMRI study:
• • Not verified SARS-CoV-2 infection with a Polymerase Chain Reaction (PCR) / rapid test / antibody review
• • Traumatic brain injury
• • Neuropsychiatric disease such as diagnosed ADHD or autism
• • Younger than 25 years or older than 55 years (to avoid the risk that the brain is not fully developed or that there is a risk of age-related changes in the brain).
• • MRI contraindications (such as metal objects in the body, fear of cramped spaces, pregnancy, body weight over 130 kg), and left-handedness (to increase the likelihood of uniform topological lateralization in the cohort).